Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

Trump orders are undermining HIV efforts by barring funds from programs built around diversity, equity, and inclusion. A Day ...

Gilead is a vast pharmaceutical multinational. With a $175 billion market capitalisation nothing about the company is going to be small. There's a large HIV treatment arm which gives it a base in ...

Storm clouds hung low above a community center in Jackson, where pastor Andre Devine invited people inside for lunch. Hoagies ...

A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence ...

The global HIV antivirals market is experiencing a period of robust growth, driven by a combination of rising global awareness, remarkable advancements in pharmaceutical research, and the increasing ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Foster City, California-based Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and ...